Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA⁺ Metastatic Colorectal Cancers.

ABSTRACT: Chimeric antigen receptor T (CAR-T) cells have shown promising efficacy in treatment of hematological malignancies, but its applications in solid tumors need further exploration. In this study, we investigated CAR-T therapy targeting carcino-embryonic antigen (CEA)-positive colorectal cancer (CRC) patients with metastases to evaluate its safety and efficacy. Five escalating dose levels (DLs) (1 × 10⁵ to 1 × 10⁸/CAR⁺/kg cells) of CAR-T were applied in 10 CRC patients. Our data showed that severe adverse events related to CAR-T therapy were not observed. Of the 10 patients, 7 patients who experienced progressive disease (PD) in previous treatments had stable disease after CAR-T therapy. Two patients remained with stable disease for more than 30 weeks, and two

SUBMITTER: Zhang C 

PROVIDER: S-EPMC5417843 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature